Related Experiment Video
Updated: Apr 4, 2026
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
Published on: February 1, 2020
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A Moffitt1, Raoud Marayati1, Elizabeth L Flate1
1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival rate of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here we have overcome this problem by applying blind source separation to a diverse collection of PDAC gene expression microarray data, including data from primary tumor, metastatic and normal samples. By digitally separating tumor, stromal and normal gene expression, we have identified and validated two tumor subtypes, including a 'basal-like' subtype that has worse outcome and is molecularly similar to basal tumors in bladder and breast cancers. Furthermore, we define 'normal' and 'activated' stromal subtypes, which are independently prognostic. Our results provide new insights into the molecular composition of PDAC, which may be used to tailor therapies or provide decision support in a clinical setting where the choice and timing of therapies are critical.
Insights
Pancreatic cancer (PDAC) research identified two tumor subtypes and two stromal subtypes using gene expression data. This discovery offers new therapeutic strategies for this lethal disease.
Area of Science:
- Genomics and Molecular Biology
- Oncology
- Bioinformatics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a poor 5-year survival rate.
- Extensive stromal infiltration in PDAC hinders the acquisition of accurate tumor-specific molecular data.
- Understanding PDAC molecular subtypes is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To overcome challenges in isolating tumor-specific molecular information from PDAC samples.
- To identify and characterize distinct molecular subtypes of PDAC.
- To define the prognostic significance of stromal subtypes in PDAC.
Main Methods:
- Application of blind source separation techniques to a comprehensive dataset of PDAC gene expression microarray data.
- Digital separation of gene expression profiles from tumor, stromal, and normal cellular components.
- Validation of identified tumor and stromal subtypes.
Main Results:
- Identification and validation of two distinct PDAC tumor subtypes.
- Discovery of a 'basal-like' PDAC subtype associated with poorer outcomes and molecular similarities to basal tumors in other cancers.
- Definition of 'normal' and 'activated' stromal subtypes, both demonstrating independent prognostic value.
Conclusions:
- The study provides novel insights into the molecular heterogeneity of PDAC.
- The identified tumor and stromal subtypes offer potential biomarkers for prognosis.
- Findings may facilitate the development of tailored therapies and clinical decision support for PDAC patients.
